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Factors contributing to the binding and reversible inactivation of gentamicin by puru-
lent exudates were studied in a simplified in vitro model consisting of purified human
polymorphonuclear leukocytes (PMNLs). Whereas intact PMNLs (106-108/ ml) bound
almost no [14C]gentamicin, freeze-thawed PMNLs showed extensive (14C]gentamicin
binding, expressed as antibiotic cosedimenting with particulate material from the lysed
PMNLs. Antibiotic binding could be related to the concentration of lysed PMNLs and
to the amount of [14C]gentamicinadded. Binding of [14C]gentamicin by lysed PMNLs
was highly sensitive to DNase I but was unaffected by RNase, Triton X-loo, or pro-
tease. Purified chromatin or DNA from either purulent exudates or lysed PMNLs
reproduced the [14C]gentamicin-binding pattern obtained with crude PMNL lysate.
These results show that gentamicin inactivation in purulent exudates can be correlated
with binding of the antibiotic to lysed PMNLs; PMNL chromatin DNA is identified as
one of the major binding factors.
Successful control of bacterial infections requires
besides other factors the adequate diffusion of
antibiotics to the sites where the pathogenic micro-
organisms reside. Antimicrobial agents are known
to bind to, and to be partially and reversibly in-
hibited by, a variety of tissue constituents, includ-
ing interstitial fluid proteins, cell membranes,
soluble intracellular proteins, and particulate in-
tracellular components [1-3]. Thus, such sedimen-
table components have been shown to bind avidly
gentamicin and polymyxin in purulent exudates,
leading to a considerable reduction of the concen-
tration of the free, biologically active drugs [4].
The mechanisms leading to the reversible inacti-
vation of aminoglycosides by purulent exudates
are largely unknown. In order to investigate this
inhibition under controlled conditions, we first
established an in vitro model of a purulent exu-
date, consisting exclusively of intact, purified,
human polymorphonuclear leukocytes (PMNLs)
suspended in a physiological buffer [5]. Under
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such conditions, no binding and/or inactivation
of gentamicin by either resting or actively phago-
cytizing PMNLs could be demonstrated, and the
decreased antibacterial effect of the aminoglyco-
side could be ascribed to its poor penetration into
the intact phagocytes, which were probably play-
ing the role of transient bacterial sanctuaries [5].
Purulent exudates, however, consist of intact as
well as lysed inflammatory cells in various propor-
tions; it was observed in the experiments described
above that disruption of the PMNLs led to a con-
siderable binding of gentamicin to the cellular
components. In vitro lysis of PMNLs therefore
turned out to be a convenient, well-controlled
system for the analysis of various parameters
influencing the binding and inactivation of amino-
glycosides and for the exploration of their binding
sites at the subcellular level. In the present study,
we define some of the factors influencing this
binding reaction and demonstrate that it can large-
ly be accounted for by aminoglycoside-Ieukocyte
chromatin interaction. Finally, we show that the
gentamicin-binding activity of lysed, purified
PMNLs occurs to the same extent as aminoglyco-
side binding with fresh, native purulent exudates
from various origins.
Materials and Methods
Antibiotics. [Methyl-14C]gentamicin sulfate
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(specific activity, 1,842 decays per min/ug) was a gift
from Schering Corp., Bloomfield, N.J. An aque-
ous stock solution of 1,000 f-tg of the free base/ml
was prepared and stored at 4 C without any signif-
icant loss of bioactivity. Injectable sisomicin
(Schering); amikacin and ampicillin (Bristol Mey-
ers S.A., Zug, Switzerland); methicillin and car-
benicillin (Beecham Pharmaceuticals, Betchworth,
England); tobramycin, vancomycin hydrochlor-
ide, and sodium cefazolin (Eli Lilly, Indianapolis,
Ind.); and penicillin G (Mycofarm, Delft, the
Netherlands) were freshly prepared as solutions
containing 1 mg of antibiotic/ml of saline for each
assay. Pure clindamycin phosphate and rifampi-
cin, donated by Upjohn (Zurich, Switzerland) and
Lepetit (Milan, Italy), respectively, were also solu-
bilized at a concentration of 1 mg/rnl, but in dis-
tilled water (clindamycin) or in 0.01 N HCI (rifam-
picin).
Preparation of leukocytes. Purified PMNLs,
or lymphomonocytes, were purified by the tech-
nique of Boyum [6]. Aliquots of the leukocyte
preparation, containing the required number of
PMNLs or lymphomonocytes (see below), were
counted in a hemacytometer and distributed in a
set of preweighed, conical sterile centrifuge tubes.
Leukocytes were sedimented for 10 min at 3,000 g
and suspended in 0.9 ml of a Dulbecco's phos-
phate-buffered saline (PBS) solution (Gibco Bio-
Cult, Glasgow, Scotland), adjusted to pH 6.0.
Unless otherwise indicated, lysed leukocyte sus-
pensions were obtained by freezing for at least 18
hr at - 20 C followed by thawing at 37 C. This
procedure led to a complete loss of cell viability [7]
as demonstrated by a >99% permeability to try-
pan blue.
Purification of chromatin. A simple pro-
cedure for isolation of interphase chromatin struc-
tures from cultured cells [8] was found to be con-
venient for the purification of chromatin from
PMNLs. In brief, 108 PMNLs were allowed to
swell at 4 C in a hypotonic solution containing 0.1
Msucrose in 0.2 rna phosphate buffer (pH 7.5) for
2 min. An equal volume of ice-cold detergent solu-
tion containing 0.5% Nonidet" P 40 (NP 40;
Shell Chemical Corp., New York, N.Y.) in 0.2 rna
EDTA (pH 7.5) was added by drops, at a rate of 1
mllmin, leading to PMNL lysis, as evidenced by
the demonstration under a microscope of nu-
merous chromatin bodies. After dispersion of the
chromatin bodies (which showed a strong ten-
dency to aggregate), the suspension was separated
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from the cell lysate by layering over a 0.1 M
sucrose-0.2 mM phosphate buffer solution, pH
8.5, and by centrifugation at 3,500 g for 20 min.
Binding off 4 C]gentamicin to PMNL lysate: as-
say of antibiotic and DNA determinations. Bind-
ing of [14C]gentamicin was expressed as the
amount of antibiotic cosedimenting (3,000 g for
10 min) with particulate material from lysed
PMNLs. The incubation conditions were as
follows: 0.1 ml of the aqueous stock solution of
[14C]gentamicin, containing 100 f-tg of free base
(240,000 decays per min), was added to 0.9 ml of a
suspension in PBS of either lysed PMNLs or pur-
ified chromatin structures. Each sample was incu-
bated for 1 hr at 37 C before centrifugation at
3,000 g for 10 min. The first supernatant con-
taining the unbound [14C]gentamicinwas carefully
separated from the wet pellet; its contribution to
the total radioactivity of the wet pellet was quanti-
tated by the procedure described below. Radioac-
tivity of the supernatant and of the pellet was esti-
, mated in a liquid scintillation counter (LS 3135-T;
Beckman Instruments, Irvine, Calif.); O.I-ml ali-
quots of the supernatant were emulsified in 5 ml
of the scintillator fluid Dimilume'" 30, which con-
tains a chemiluminescence inhibitor (Packard In-
strument Co., Downers Grove, 111.), and counted.
The [1 4C]gentamicin present in the wet pellet was
quantitatively extracted in a 5070 solution of
trichloroacetic acid (TCA), and O.I-ml aliquots
were emulsified in 5 ml of Dimilume 30 and
counted. The counting efficiency was optimal
(90%), and the cpm data were directly converted
into ng of [14C]gentamicin using the appropriate
conversion factor. The extraction step in TCA was
carried out at 90 C for 10 min because it extracted
simultaneously the nucleic acids [9] of the sam-
ples, which were assayed for DNA by the method
of Dische [10]. After heating, the samples were
cooled at 4 C for 15 min before centrifugation at
3,000 g for 10 min.
For small chromatin fragments, the following
modifications of the antibiotic-binding assay were
introduced: at the end of the 60-min incubation at
37 C with [1 4C]gentamicin in PBS, the chromatin
fragments or the purified DNA was sedimented at
290,000 g for 120 min at 4 C. The pellet was first
suspended in TNE (20 mM Tris-HCI, 40 mM NaCI,
1 mM EDTA; pH 7.5), to which one volume of
10% TCA was added. This time, extraction of
[1 4C]gentamicin was carried out in the cold (4 C)
because the suspension was too dilute to allow
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detection of DNA by the colorimetric method
[10]. After precipitation in cold 5% TCA, the
sedimented (3,000 g for 10 min) nucleic acids were
selectively extracted in 0.5 ml of 5% TCA at 90 C
for 10 min and assayed colorimetrically[10] for
DNA.
The reproducible, full recovery of (14C]gentami-
cin in the supernatants and in the pellet extracts
also required an accurate volumetric estimation of
the fluids containing the radioactive antibiotic.
This estimation was done by gravimetry, since the
density either of supernatant fluid or of the TCA
pellet extract was close to that of water «1.02).
Volumetric estimation of the wet pellet was also
done by gravimetry. The contribution of contami-
nating supernatant fluid to the wet pellet was esti-
mated by the formula WSN =Wwp - Wo, where
WSN is the weight of supernatant fluid, Wwp is the
weight of the wet pellet, and Wo is the weight of
the heat-dried pellet. The value of Wo turned out
to be rvl mg for 107 leukocytes. When intact leuko-
cytes were tested in the binding assay, the contri-
bution of their intracellular fluid to the weight of
the wet pellet was also taken into consideration in
estimating the weight of contaminating superna-
tant fluid according to the modified formula
WSN = Wwp- Wo - W1P , where W1P is the weight of
intracellular fluid. This value has been shown to
be 2 mg/107 leukocytes [11].
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Figure 1.. Binding of 100 tJg of [14C]gentamicin in a
l-ml assay by purified intact (0) or freeze-thawed
polymorphonuclear leukocytes (PMNL) as a function of
cell concentration: (.) = sediment; (.&) = superna-
tant. Similar binding values were obtained with a native,
purulent empyema, adjusted for an equal number of
trypan blue-positive PMNL: «») = sediment; (4) =
supernatant.
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Binding assay with nonradioactive antibi-
otics. Suspensions (0.9 ml) of 5 x 107 lysed
PMNLs in PBS were supplemented with 0.1 ml of
a 10-fold concentrated solution of the nonradioac-
tive antibiotic to be tested. The conditions of incu-
bation and of sedimentation were identical to
those used in the [14C]gentamicin-binding assay.
The supernatant and the pellet, suspended in PBS,
were assayed microbiologically using a modified
agar-well method [12] and Bacillussubtilis ATCC
6633 as the test organism for all of the antibiotics
tested, except for carbenicillin (Pseudomonas
aeruginosa NCTC 10490) and cloxacillin, clinda-
mycin, and rifampicin (Sarcina lutea NCTC
8340). Standard curves were obtained by dilution
of the antibiotics in PBS.
Enzyme or detergent pretreatment of lysed
PMNLs and of purified chromatin. Lysed
PMNLs (107) or purified chromatin at an equival-
ent DNA content was sedimented at 3,000 g for 10
min, suspended, and incubated for 60 min at 37 C
with one of the following enzymes or detergent:
(1) pancreatic DNase I (Serva Feinbiochemica,
Heidelberg, West Germany), 50 Ilg/ml in 10 mM
Tris-HCI, 10 mM NaCI, 3 mM MgCb (pH 7.4); (2)
the same buffer without DNase; (3) pancreatic
RNase A (Serva Feinbiochemica), 20 Ilg/ml in 10
mM Tris-HCI, 10 mM NaCI (pH 7.4); (4) protein-
300
«
z
'7
c;;
u
en
:1. 200
"U
c:
:J
0
.a
c: ! ~U 100E /~~(1jC
e.>
en
en
c:
a -r---"""!---,-- I -,----,
a 100 200 300 400 500 600 700 800
Total amount of gentamicin added (Ilg)
Figure 2. Binding of [14C]gentamicin in a l-ml assay
by sediments of 107 purified freeze-thawed polymor-
phonuclear leukocytes (PMNLs) (.) or by purified
chromatin from 107 PMNLs (0), suspended in
phosphate-buffered saline as a function of the total
amount of antibiotic added. All binding values are ex-
pressed as ng of gentamicin bound/tJg of leukocyte
DNA; each value represents the mean of triplicate assays
± SEM.
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ase K (Merck, Darmstadt, West Germany), 100
IJg/ml in 5 mM Tris-HCI, 5 mM NaCI, 5 mM EDTA
(pH 8.0); (5) 0.2% Triton X-100 (Merck) in 5 mM
Tris-HCI, 5 mx NaCI, 5 mu EDTA (pH 8.0).
After incubation, the residual material was sedi-
mented for 10 min at 3,000 g and resuspended in
0.9 ml of PBS. An aliquot (0.1 ml) of the 1 mg of
[ 14C]gentamicin/ ml stock solution was added to
each tube, and the binding assay was performed as
described above.
Statistical analysis. Each individual assay con-
dition was tested in triplicate tubes, with differ-
ences in results analyzed by Student's t-test.
Results
Gentamicin binding of lysed peripheral PMNLs
and of PMNLs obtained from purulent exu-
dates. The gentamicin-binding activities of
PMNLs incubated under different conditions in
PBS are summarized in figure 1. Whereas intact,
freshly collected PMNLs bound almost no
[14C]gentamicin, lysed PMNLs showed extensive
binding, which was dependent on the number of
lysed cells added to the system. While 108 lysed
PMNLs bound 50 IJg of gentamicin in a 1-ml
assay, almost identical results were obtained with
a native preparation of a purulent exudate con-
taining the same number of trypan blue-positive
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PMNLs. Binding of the aminoglycoside by lysed,
purified PMNLs or empyema at various concen-
trations was corroborated by the concomitant de-
crease in [14C]gentamicin concentration in the su-
pernatant fluid. The same results were obtained
with a preparation of purified, lysed lymphocytes
and monocytes (data not shown). Control experi-
ments, performed either with a suspension or with
a washed sediment of lysed PMNLs, showed iden-
tical gentamicin binding; therefore, further bind-
ing assays were performed with leukocytic sedi-
ments washed in PBS.
Gentamicin-binding conditions in the presence
of lysed PMNLs. In the presence of a constant
amount of a leukocyte sediment equivalent to 107
lysed PMNLs, [14C]gentamicin binding in the
presence of increasing concentrations of the anti-
biotic was a saturable process (figure 2). From
0.75 IJg to 100 IJg of [14C]gentamicin/ml, the
amount of antibiotic bound to the leukocytic sedi-
ment was proportional to the total amount of gen-
tamicin added (eight concentrations tested, data
not shown), whereas with >200 ug/rnl the binding
process was saturable. To correct for the occa-
sional variability in the PMNL counts of the sam-
ples and to correlate the binding results with those
obtained in presence of chromatin (see below), all
of the binding values were expressed as a function
of the DNA content of the sedimented, lysed
Table 1. Binding of various antibiotics by lysed human polymorphonuclear leukocytes (PMNLs).
Amount of antibiotic (I-lg)
Bound to Bound to Total
Antibiotic Total added sediment" supernatant recovered
Gentamicin 10 3.7 ± 0.8 6.3 ± 0.1 10.0 ± 0.8
Tobramycin 10 4.6 ± 1.5 5.0 ± 0.04 9.6 ± 1.5
Sisomicin 10 3.7 ± 0.7 6.3 ± 0.1 10.0 ± 0.7
Neomycin 10 4.6 ± 1.5 3.0 ± 1.0 7.6 ± 0.8
Amikacin 20 1.8 ± 0.2 15.1 ± 1.0 16.9 ± 1.2
Penicillin G 100 1.6 99.0 100.6
Ampicillin 100 1.1 93.0 94.1
Methicillin 100 0.1 90.0 90.1
Cloxacillin 100 2.6 95.0 97.6
Carbenicillin 100 <6.0t 101.0 <107.0
Cefazolin 100 0.3 91.0 91.3
Vancomycin 100 7.9 89.6 97.5
Vancomycin 10 1.8 7.3 9.1
Clindamycin 10 <LOt 11.0 <12.0
Rifampicin 10 1.3 10.8 12.1
NOTE. See Materials and Methods for procedures used in the binding assay and the microbiological assay for antibiotic. Each
binding assay was performed in a total volume of 1 ml. Where indicated, data are means of triplicate assays ± SEM.
• Each sediment corresponded to 5 x 107 lysed PMNLs.
t The sensitivity limit of the microbiological assay.
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Table 2. Binding of (14C]gentamicin (100 lAg/ml) by lysed polymorphonuclear leukocytes (PMNLs) (107/ml) pre-
treated with various enzymes or nonionic detergent.
Pretreatment
None
RNase A
Triton X-l00
Proteinase K
DNase 1
Lysed PMNL sediment
['4C]gentamicin bound (J,lg)
8.79 ± 0.78
8.80 ± 0.32
8.86 ± 0.46
11.87 ± 0.50
1.60 ± 0.26*
DNA content (J,lg)
73.7 ± 2.0
70.3 ± 2.7
65.5 ± 3.1
77.1 ± 14.4
25.1 ± 3.1*
[14C]gentamicin bound
(ng)/DNA content (Jlg)
119 ± 11
125 ± 4
135 ± 4
154 ± 43
64 ± 16
NOTE. See Materials and Methods for preincubation and binding assay procedures. Data are means of triplicate assays ± SEM.
* P <0.001 compared with untreated sediment.
PMNLs; thus, 107 lysed PMNLs had a mean DNA
content of 70 I-tg and bound 17 I-tg of gentamicin
under saturating conditions.
Binding/inhibition of other antibiotics by lysed
PMNLs. Besides gentamicin, a number of other
antibiotics was tested by microbiological assay for
their binding by lysed PMNLs (table 1). Binding
and inhibition by 5 X 107 lysed PMNLs could be
demonstrated mainly with antibiotics of the am-
inoglycoside group. None of the penicillins or ce-
phalosporins tested showed any binding with the
leukocytic sediments, and little inactivation was
observed with vancomycin and rifampicin. Final-
ly, fully biologically active aminoglycosides could
be recovered from the sediment (table 1), a result
demonstrating the reversibility of the inactivation
process.
Identification of PMNL substrates responsible
for aminoglycoside binding. In an attempt to de-
fine the PMNL substrates with gentamicin-bind-
ing activity, the leukocyte sediments were predi-
gested with various enzymes or nonionic deter-
gents and tested for residual gentamicin-binding
activity (table 2). Neither RNase nor Triton X-100
nor proteinase K removed any binding activity
from the leukocytic sediments; in comparison,
pancreatic DNase I decreased the activity by
>80070 (P < 0.001). DNA assay of the residual ma-
terial after the various predigestions indicated that
66% of the DNA originally present in the leukocy-
tic sediment had been digested by DNase I (P <
0.001), in contrast to the lack of effect of the other
agents. Incomplete digestion of chromatin DNA
by DNase I is thought to have resulted from its
protection by chromatin proteins [13] and proba-
bly explains the residual 20% binding activity of
the leukocytic sediment after digestion.
To assess further the correlation between the
role of DNA-containing material and its gentami-
cin-binding activity, purified PMNL chromatin
was prepared and incubated in the presence of
labeled antibiotic. For a constant amount of puri-
fied chromatin (figure 2, bottom curve) extracted
from 107 PMNLs, ['4C]gentamicin binding as a
function of aminoglycoside concentration ex-
hibited the same saturation process previously
demonstrated with the same number of lysed
PMNLs (figure 2, top curve). Although the two
systems were saturated at the same value of total
gentamicin added, the purified chromatin samples
Table 3. Binding of [14C]gentamicin (100 lAg/ml) by the purified chromatin fraction obtained from polymorpho-
nuclear leukocytes (107/ml) pretreated with various enzymes.
Pretreatment
None
RNase A
Proteinase K
DNase I
Sonication plus DNase I
Chromatin
[14C]gentamicin bound (J,lg)
5.52 ± 0.11
5.33 ± 0.10
7.62 ± 0.40*
3.78 ± 0.10*
0.12 ± 0.04*
DNA content (J,lg)
51.3 ± 0.3
57.6 ± 0.3
65.6 ± 1.2
36.3 ± 2.4t
11.3 ± 2.4*
[14C]gentamicin bound
(ng)/DNA content (Jlg)
108 ± 3
92 ± I
116 ± 5
104 ± 7
11 ± 1*
NOTE. See Materials and Methods for the preincubation and binding assay procedures. Data are means of triplicate assays
± SEM.
* P < 0.001 compared with untreated, purified chromatin.
t P < 0.005 compared with untreated, purified chromatin.
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bound only 40% of the gentamicin bound by lysed
PMNLs under saturating conditions. Such
lowered efficiency of gentamicin-binding activity
exhibited by the purified chromatin fractions
probably resulted from their highly aggregated
state during incubation in PBS for the binding
assay.
Purified chromatin was also digested by differ-
ent enzymes as described previously for lysates of
PMNLs (table 3). Neither RNase A nor proteinase
K decreased DNA content or binding activity of
the purified chromatin. DNase I was less active on
purified chromatin in its aggregated state than on
leukocyte sediments; thus, 68070 of the chromatin
DNA resisted digestion by DNase I, and 71% of
the [14C]gentamicin-binding activity was still pres-
ent at the end of the preincubation phase. Brief
successive treatments of the purified chromatin
with DNase I for 5 min improved the DNA diges-
tion, with >80% of the DNA being removed, ac-
companied by a similar loss in gentamicin-binding
activity (duplicate assays, data not shown). Final-
ly, the solubilization of purified chromatin was
improved by brief sonication and centrifugation at
high speed (290,000 g for 2 hr); the sonicated
chromatin pretreated with DNase I lost 97% of its
gentamicin-binding activity, while DNA assays of
the high-speed pellets indicated that 90070 of the
chromatin DNA had been hydrolyzed (table 3).
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These results taken together suggested that the
DNA fraction is essential for the gentamicin-bind-
ing activity of purified chromatin. In contrast, the
presence of chromatin histone and nonhistone
proteins was of minor importance since their selec-
tive extraction by either 0.2 N H 2S04 or 0.4 M
NaCl did not remove any gentamicin-binding ac-
tivity (data not shown).
Correlation between gentamicin-binding activ-
ity of lysed PMNLs and of native, purulent exu-
dates. To correlate gentamicin binding of lysed
PMNL suspensions with that of naturally occur-
ring purulent exudates, three of such exudates ob-
tained from three patients were incubated at a
concentration of 2-10 x 107 cells/ml with 10 lAg or
100 lAg of gentamicin under various conditions
(table 4). Binding to sedimentable material was in
good agreement with that demonstrated in figure 1
and could be further increased by incubation in
hypotonic medium or by freeze-thawing. Finally,
the role of DNA as a main binding substrate of
. gentamicin in a fresh, native, purulent exudate
was confirmed by the demonstration that purified
DNA from purulent exudate from patient no. 1,
when preincubated with 100 lAg of [14C]gentamicin
for 60 min and ultracentrifuged at 290,000 g for
120 min, exhibited a binding of 18 lAg of the antibi-
otic to 62 lAg of purified DNA. The ratio of 290 ng
of [14C]gentamicin bound/ug of purified DNA
Table 4. Cellular binding of [14C]gentamicin by purulent exudates: role of cell lysis and of incubation conditions.
[1·C]gentamicin (J,tg)
Leukocytes Recovered in
excluding Recovered in freeze-thawed
Patient no./origin Leukocyte trypan blue Total native PMNL PMNL sedi-
(microorganism) count (0J0) added sediment ment
I, perianal abscess
(Staphylococcus aureus) 10 X 107 90 100· 13.9 33.0
2, pleural empyema (anaerobes) 10 x 107 60 100· 9.6 34.0
10· 2.4 4.8
3, abdominal abscess
(Escherichia coil) 2 x 107 NO lOOt 8.2 15.0
lOOt 30.8 35.8
Purified circulating
human PMNLs I x 107 100 lOOt 1.0 9.8
lOOt 15.9 16.1
NOTE. Each binding assay was performed in a total volume of 1 ml. PMNL = polymorphonuclear leukocyte; NO = not
done.
• Uncentrifuged exudate.
t Washed and suspended in phosphate-buffered saline at its original concentration.
t Washed and suspended in distilled water at its original concentration.
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measured was in good agreement with that ob-
tained with lysed PMNLs under saturating condi-
tions (figure 2).
Discussion
During the last decade, increased interest has de-
veloped in the penetration of antibiotics into nor-
mal and infected tissues, in order to delineate
possible factors leading to therapeutic failure in
localized infections [1]. Such studies have been
hampered by various methodological problems,
such as the complex constitution of tissue homo-
genates, the individual characteristics of each anti-
biotic, and the influence of various physicochem-
ical parameters [2].
As a special case of interaction between antibi-
otic and tissue constituents, Bryant and Ham-
mond [4] have recently demonstrated in a simple
assay system that aminoglycosidic antibiotics bind
avidly, but reversibly, to a homogenized purulent
exudate. Such an interaction, resulting in partial
fluid-phase inactivation of the antibacterial
agents, offered a plausible explanation for the dif-
ficulty in sterilizing pseudomonas abscesses [4].
These studies, although contributing to our under-
standing of the fate of aminoglycosidic antibiotics
in purulent exudates, did not delineate either the
binding conditions or the binding substrate(s) of
such exudates, although intact or lysed PMNLs or
subcellular fractions thereof were candidates to be
considered [2-4].
In a previous study [5], we were able to demon-
strate that gentamicin bound poorly to highly
purified, intact human PMNLs. In the present
study, we provide evidence that an "artificial
purulent exudate," obtained by lysis of human
PMNLs under well-controlled conditions, binds
gentamicin and other aminoglycosidic antibiotics
by virtue of its high content in human PMNL-de-
rived chromatin. The adequacy of our in vitro
model as a paradigm of a purulent exudate for
these experiments is suggested by the identical gen-
tamicin-binding curves obtained by equal numbers
of either purified, lysed PMNLs or leukocytes ob-
tained from a native exudate incubated under
identical conditions (figure 1, table 1); gentamicin-
binding activity of purulent exudates, centrifuged
and resuspended in PBS and assayed without
freeze-thawing, was superimposable on that ob-
tained with purified PMNL sediments lysed to ob-
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tain an equivalent number of trypan blue-positive
cells.
Before reviewing the chromatin-binding experi-
ments, several aspects of our in vitro cellular
model should be discussed. (1) As shown in table 1
and figure 1, binding of aminoglycosides to lysed
PMNL sediments of pus correlated with an equiv-
alent decrease in antimicrobial activity of the su-
pernatants, an observation indicating that there
was no additional soluble inhibitory factor(s) in-
volved in our system. Thus, binding to soluble
acid mucopolysaccharides [14] was negligible in
our system. (2) Binding of [14C]gentamicin to
lysed PMNLs or pus resulted in an equivalent loss
of its antimicrobial activity, and antibacterial ac-
tivity could be restored by extraction of the counts
from the pellet. The results of these experiments
confirmed that the binding process was reversible,
as was suggested by the results of Bryant and
Hammond [4] under less physiologic conditions.
(3) The sensitivity of the radioactive assay as well
as the intensity of the gentamicin binding to lysed
PMNLs allowed us to perform most studies at a
low cell concentration. This last point had several
advantages, including a more accurate gravimetric
estimation of the packed leukocyte volume (their
dry weight not exceeding 1 mg), a better control of
the ionic strength of the incubation solution, and
an easily attainable saturation concentration of
gentamicin. Finally, Ca" and Mg'" liberated from
lysed PMNLs could not influence our microbio-
logical assays of the various aminoglycosidic anti-
biotics tested, since their contribution of the incu-
bation was <1 microequivalent/TO' lysed cells.
As shown in figures 1 and 2, binding of genta-
micin by lysed PMNLs or native purulent exudate
could be reproduced by incubation of gentamicin
with chromatin isolated from an equal number of
purified PMNLs. Although the curves showed
similar saturation kinetics, reaching their plateaus
at a gentamicin concentration of 200 tJg/ml, the
binding activity of the purified chromatin was
40% of the values obtained in the corresponding
PMNL sediment for an equivalent DNA concen-
tration. Since purified chromatin was highly
aggregated in PBS, as was shown by other investi-
gators [8], it might have reduced the number of
gentamicin-binding sites under saturating condi-
tions; alternatively, purification of chromatin
might have slightly reduced the binding affinity of
the preparation. Additional circumstantial evi-
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dence of the important role played by the DNA-
containing chromatin material in the binding of
[ ' 4C]gentamicin was obtained by showing that
only DNase treatment, but not incubation with
pronase, RNase, or Triton X-1OO, abolished the
cosedimentation of the antibiotic either with lysed
PMNLs or with purified chromatin. Direct dem-
onstration of gentamicin binding to DNA-con-
taining material was obtained by incubation of the
DNA, purified from the purulent exudate used in
figure 1, with the antibiotic, followed by ultracen-
trifugation. These results are in accord with pre-
vious observations; aminoglycosidic antibiotics
such as streptomycin bind avidly to DNA and can
be used as their precipitating agents [15, 16].
The clinical relevance of the present and pre-
vious observations is as yet not fully defined [4,
16]. Binding of aminoglycosides was substantially
higher in a study by Bryant and Hammond than in
ours, probably as a result of laboratory manipula-
tions such as homogenization and resuspension in
hypotonic medium [4]; these factors influenced
dramatically the degree of binding of native,
purulent exudates, as shown in table 4. Neverthe-
less, a 10%-30% inactivation of aminoglycosides
by a native, purulent exudate could have impor-
tant consequences in association with other fac-
tors present in inflammatory exudates such as low
pH and low Po2 , both of which are known to
affect adversely the antibacterial effect of amino-
glycosides [17, 18]. Experiments performed on an
animal model may help to clarify these aspects.
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